We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Septic Shock (EUPHRATES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01046669
Recruitment Status : Completed
First Posted : January 12, 2010
Results First Posted : February 6, 2019
Last Update Posted : February 26, 2019
Information provided by (Responsible Party):
Spectral Diagnostics (US) Inc.

Brief Summary:
To compare the safety and efficacy of the PMX cartridge based on mortality at 28-days in subjects with septic shock who have high levels of endotoxin and are treated with standard medical care plus use of the PMX cartridge, versus subjects who receive standard medical care alone.

Condition or disease Intervention/treatment Phase
Septic Shock Endotoxemia Device: TORAYMYXIN PMX-20R (PMX cartridge) Other: Standard medical care for septic shock Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 450 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemia and Septic Shock
Actual Study Start Date : June 2010
Actual Primary Completion Date : July 2016
Actual Study Completion Date : June 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Shock

Arm Intervention/treatment
Sham Comparator: Control
Standard medical care for septic shock
Other: Standard medical care for septic shock
Standard medical care for septic shock

Experimental: Treatment
Two (2) PMX cartridges will be administered approximately 24 hours apart plus standard medical care for septic shock
Device: TORAYMYXIN PMX-20R (PMX cartridge)
TORAYMYXIN PMX-20R (PMX cartridge), Extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).

Other: Standard medical care for septic shock
Standard medical care for septic shock

Primary Outcome Measures :
  1. Mortality [ Time Frame: 28 days ]
    Compare mortality at 28 days in subjects treated with standard medical care plus PMX cartridge, versus subjects who received standard medical care alone

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hypotension requiring vasopressor support
  • The subject must have received intravenous fluid resuscitation
  • Documented or suspected infection
  • Endotoxin Activity Assay ≥ 0.60 EAA units
  • Evidence of at least 1 new onset organ dysfunction

Exclusion Criteria:

  • Inability to achieve or maintain a minimum mean arterial pressure (MAP) of 65mmHg
  • Subject has end stage renal disease and requires chronic dialysis
  • There is clinical support for non-septic shock
  • Subject has had chest compressions as part of CPR
  • Subject has had an acute myocardial infarction (AMI)
  • Subject has uncontrolled hemorrhage
  • Major trauma within 36 hours of screening
  • Subject has severe granulocytopenia
  • HIV infection with a last known or suspected CD4 count of <50/mm3
  • Subject has sustained extensive third-degree burns
  • Body weight < 35 kg (77 pounds)
  • Known hypersensitivity to polymyxin B
  • Subject has known sensitivity or allergy to heparin
  • Subject has screening MOD score of ≤9

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01046669

Layout table for location information
United States, Alabama
Birmingham, Alabama, United States
United States, Arizona
Tucson, Arizona, United States
United States, Arkansas
Little Rock, Arkansas, United States
United States, California
Loma Linda, California, United States
San Diego, California, United States
Stanford, California, United States
United States, Colorado
Colorado Springs, Colorado, United States
United States, Delaware
Newark, Delaware, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Georgia
Augusta, Georgia, United States
United States, Idaho
Idaho Falls, Idaho, United States
United States, Illinois
Oak Park, Illinois, United States
Peoria, Illinois, United States
United States, Iowa
Iowa City, Iowa, United States
United States, Kentucky
Hazard, Kentucky, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Springfield, Massachusetts, United States
United States, Michigan
Ann Arbor, Michigan, United States
Detroit, Michigan, United States
United States, Minnesota
Rochester, Minnesota, United States
United States, Mississippi
Jackson, Mississippi, United States
United States, Missouri
Saint Louis, Missouri, United States
United States, Nebraska
Omaha, Nebraska, United States
United States, New Jersey
Camden, New Jersey, United States
United States, New York
New York, New York, United States
United States, North Carolina
Greenville, North Carolina, United States
United States, Ohio
Columbus, Ohio, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
Pittsburgh, Pennsylvania, United States
United States, Tennessee
Chattanooga, Tennessee, United States
United States, Texas
Houston, Texas, United States
San Antonio, Texas, United States
United States, Virginia
Richmond, Virginia, United States
Canada, Alberta
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Canada, British Columbia
Victoria, British Columbia, Canada
Canada, Ontario
Oshawa, Ontario, Canada
Ottawa, Ontario, Canada
Toronto, Ontario, Canada
Canada, Quebec
Quebec City, Quebec, Canada
Sponsors and Collaborators
Spectral Diagnostics (US) Inc.
Layout table for investigator information
Principal Investigator: Phillip Dellinger, Dr. Cooper Health System
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Spectral Diagnostics (US) Inc.
ClinicalTrials.gov Identifier: NCT01046669    
Other Study ID Numbers: SDI-PMX-NA001
First Posted: January 12, 2010    Key Record Dates
Results First Posted: February 6, 2019
Last Update Posted: February 26, 2019
Last Verified: February 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Shock, Septic
Pathologic Processes
Systemic Inflammatory Response Syndrome